Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Who May Be Eligible (Plain English)

IWho May Qualify: - Pregnant women between 20 and 36 weeks of gestation - Age between 18 and 45 years - Attending the antenatal clinic at the study site Who Should NOT Join This Trial: - Chronic hypertension - Renal disease - Diabetes mellitus - Multiple gestations - Autoimmune disorders Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders

Locations (1)

Bint Al Huda Maternity Hospital
Nasiriyah, Dhi Qar, Iraq